Similarly, recombinant IL-1β was administered just after BD was induced since our experience and preliminary control assays indicated that it was the optimal pretreatment time to eliminate the protective effects of IL-6 or IL-10, which occur during reperfusion time in liver grafts. Here, IL1B is linked to Behcet disease.